Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

Introduction The PIONEER 7 trial demonstrated superior glycemic control and weight loss with once-daily oral semaglutide with flexible dose adjustment versus sitagliptin 100 mg in type 2 diabetes. This 52-week extension evaluated long-term oral semaglutide treatment and switching from sitagliptin to...

Full description

Bibliographic Details
Main Authors:	Ann Mertens, John B Buse, Bruce W Bode, Young Min Cho, Erik Christiansen, Christin L Hertz, Morten A Nielsen, Thomas R Pieber
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-12-01
Series:	BMJ Open Diabetes Research & Care
Online Access:	https://drc.bmj.com/content/8/2/e001649.full

Similar Items

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
by: Juris J. Meier
Published: (2021-06-01)

Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-07-01)

Advances in GLP-1 treatment: focus on oral semaglutide
by: Freddy G. Eliaschewitz, et al.
Published: (2021-09-01)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
by: Baptist Gallwitz, et al.
Published: (2021-06-01)

The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01)

Semaglutide-associated bullous pemphigoid
by: Clayton P. Burruss, BS, et al.
Published: (2021-09-01)

Acute Kidney Injury Associated With Semaglutide
by: David J. Leehey, et al.
Published: (2021-03-01)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
by: Pearson S, et al.
Published: (2019-12-01)

Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide
by: Abramson, Alex, et al.
Published: (2022)

Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide
by: Abramson, Alex, et al.
Published: (2022)

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
by: Hassan A. Alsugair, et al.
Published: (2021-08-01)

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes
by: Chapman, R.H, et al.
Published: (2021)

Farmakologisk behandling vid fetma : Semaglutid versus liraglutid
by: Nilsson, Natalié
Published: (2021)

Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis
by: Ping Zhong, et al.
Published: (2021-10-01)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
by: Michael A. Nauck, et al.
Published: (2021-03-01)

Clinical potential of treatment with semaglutide in type 2 diabetes patients
by: Michael E Røder
Published: (2019-12-01)

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
by: Jan Maurik van den Heuvel, et al.
Published: (2020-04-01)

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes
by: Rune V. Overgaard, et al.
Published: (2021-09-01)

More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes
by: Paul Langley
Published: (2020-02-01)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
by: Juris J. Meier, et al.
Published: (2021-09-01)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
by: Mansoor Husain, et al.
Published: (2020-09-01)

Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes
by: Xin Zhang, et al.
Published: (2021-07-01)

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
by: Gomez-Peralta F, et al.
Published: (2019-02-01)

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes
by: Rafael Simó, et al.
Published: (2021-07-01)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
by: Ildiko Lingvay, et al.
Published: (2020-11-01)

Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
by: Hwi Seung Kim, et al.
Published: (2021-09-01)

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Fang-Hong Shi, et al.
Published: (2018-06-01)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
by: Thomas Hansen, et al.
Published: (2020-12-01)

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
by: Donna H. Ryan
Published: (2021-09-01)

Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China
by: Shanshan Hu, et al.
Published: (2021-06-01)

Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing
by: David C Klonoff, et al.
Published: (2021-06-01)

Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient
by: Gabriele Costanzo, et al.
Published: (2021-09-01)

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report
by: Damas-Fuentes, M., et al.
Published: (2022)

A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease
by: Lyndon Marc Evans, et al.
Published: (2021-07-01)

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways
by: Günaj Rakipovski, PhD, et al.
Published: (2018-12-01)

An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain
by: Santiago Tofé, et al.
Published: (2021-03-01)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
by: Lawrence A. Leiter, et al.
Published: (2019-06-01)

Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial
by: Mojca Jensterle, et al.
Published: (2021-07-01)

Hypoglycemia associated with off-label sitagliptin use
by: Heather P Whitley, et al.
Published: (2008-11-01)

Oral administration of sitagliptin activates CREB and is neuroprotective in murine model of brain trauma
by: Brian Dellavalle, et al.
Published: (2016-12-01)

Cannot write session to /tmp/vufind_sessions/sess_fl5v92p8ojv73ef9719un1pntk